# Besponsa (inotuzumab ozogamicin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/inotuzumab-ozogamicin

> The FDA approved Besponsa (inotuzumab ozogamicin), sponsored by PFIZER INC (PFE), on August 17, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Besponsa (inotuzumab ozogamicin) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### August 17, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761040 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170817, review_priority PRIORITY; sponsor_name WYETH PHARMS INC; product BESPONSA (INOTUZUMAB OZOGAMICIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761040%22

### March 6, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761040 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240306, review_priority PRIORITY; sponsor_name WYETH PHARMS INC; product BESPONSA (INOTUZUMAB OZOGAMICIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761040%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/inotuzumab-ozogamicin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Besponsa (inotuzumab ozogamicin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/inotuzumab-ozogamicin

```bibtex
@misc{secapidev_pdufa_inotuzumab_ozogamicin_20261116,
  title        = {Besponsa (inotuzumab ozogamicin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/inotuzumab-ozogamicin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_inotuzumab_ozogamicin_20261116","title":"Besponsa (inotuzumab ozogamicin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/inotuzumab-ozogamicin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
